17.38

1.86% -0.33

After Hours: 17.06 -0.32 -1.84%

Arcutis Biotherapeutics Inc (ARQT)

Overview News Price History Option Chain Financials Why ARQT Down? Discussions Forecast

Arcutis Biotherapeutics Inc stock is traded at $17.38, with a volume of 2.08M. It is down -1.86% in the last 24 hours and up +10.21% over the past month. Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Previous Close:

$17.71

Open:

$17.57

24h Volume:

2.08M

Relative Volume:

1.21

Market Cap:

$2.08B

Revenue:

$59.61M

Net Income/Loss:

$-262.14M

P/E Ratio:

-4.4337

EPS:

-3.92

Net Cash Flow:

$-247.49M

1W Performance:

+0.52%

1M Performance:

+10.21%

6M Performance:

+4.70%

1Y Performance:

+71.40%

1-Day Range:

$17.00

$17.82

1-Week Range:

$16.62

$17.88

52-Week Range:

$8.03

$18.15

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name

Arcutis Biotherapeutics Inc

Sector

Healthcare (1154)

Industry

Biotechnology (647)

Phone

805-418-5006

Address

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Employee

342

Twitter

@ArcutisBio

Next Earnings Date

2024-12-06

Latest SEC Filings

ARQT's Discussions on Twitter

Compare ARQT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARQT Arcutis Biotherapeutics Inc	17.38	2.12B	59.61M	-262.14M	-247.49M	-3.92
VRTX Vertex Pharmaceuticals Inc	383.12	99.25B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	591.99	63.46B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	453.56	59.27B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	736.76	44.78B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	334.40	37.75B	3.81B	-644.79M	-669.77M	-6.24

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Initiated	Goldman	Neutral
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-28-24	Initiated	Jefferies	Buy
Jan-03-24	Upgrade	Mizuho	Neutral → Buy
Oct-26-23	Downgrade	Mizuho	Buy → Neutral
Oct-13-23	Downgrade	Goldman	Buy → Neutral
Sep-07-22	Initiated	Needham	Buy
Mar-17-22	Initiated	Goldman	Buy
Jun-30-21	Initiated	Mizuho	Buy
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-09-20	Upgrade	Goldman	Neutral → Buy
Oct-08-20	Initiated	Truist	Buy
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight
Feb-25-20	Initiated	Cowen	Outperform
Feb-25-20	Initiated	Goldman	Neutral
Feb-25-20	Initiated	Guggenheim	Buy

View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

12:41 PM

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 4.5% HigherStill a Buy? - MarketBeat

12:41 PM

Sep 20, 2025

Triumph Capital Management Acquires Shares of 29,244 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Sep 20, 2025

Published on: 2025-09-20 11:38:58 - khodrobank.com

Sep 20, 2025

Sep 19, 2025

Stock Analysis: Is Arcutis Biotherapeutics Inc stock good for income investors2025 Trading Volume Trends & Weekly Chart Analysis and Guides - khodrobank.com

Sep 19, 2025

Sep 18, 2025

Analyst Upgrade: What is Arcutis Biotherapeutics Inc. s 5 year growth outlookTrade Entry Summary & Community Driven Trade Alerts - khodrobank.com

Sep 18, 2025

EPS Watch: Can Viavi Solutions Inc maintain its current growth rateEarnings Risk Report & Weekly High Conviction Trade Ideas - khodrobank.com

Sep 18, 2025

Breakout Move: Can Arcutis Biotherapeutics Inc sustain earnings growthJuly 2025 WrapUp & Safe Swing Trade Setup Alerts - khodrobank.com

Sep 18, 2025

Take Profit: What are the future prospects of Arcutis Biotherapeutics IncQuarterly Risk Review & Stepwise Trade Execution Plans - خودرو بانک

Sep 18, 2025

Anti-Aging Market Surges as $101M Competition Drives Demographic Revolution - Baystreet.ca

Sep 18, 2025

Income Plays: Will FBLA face regulatory challengesRecession Risk & Reliable Intraday Trade Alerts - خودرو بانک

Sep 18, 2025

Invst LLC Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Sep 18, 2025

Sep 17, 2025

Market Review: Is ProShares Trust ProShares UltraPro Short S&P500 a good ESG investmentJuly 2025 WrapUp & Expert-Curated Trade Recommendations - خودرو بانک

Sep 17, 2025

CEO Change: Can NanoViricides Inc continue delivering strong returnsWeekly Risk Summary & Safe Entry Zone Tips - خودرو بانک

Sep 17, 2025

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress - The Manila Times

Sep 17, 2025

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress | Dow Theory Letters - FinancialContent

Sep 17, 2025

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award - GlobeNewswire

Sep 17, 2025

Fred Alger Management LLC Invests $568,000 in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Sep 17, 2025

Sep 16, 2025

FOMO Trade: Does Arcutis Biotherapeutics Inc stock reflect fundamentals2025 Sector Review & Low Drawdown Trading Techniques - خودرو بانک

Sep 16, 2025

Arcutis Biotherapeutics’ ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Award for Innovation in Dermatology - Quiver Quantitative

Sep 16, 2025

Aug Big Picture: Can Arcutis Biotherapeutics Inc stock outperform in a bear market2025 Dividend Review & AI Enhanced Trading Signals - khodrobank.com

Sep 16, 2025